|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2005; 46:697-704, doi:10.1016/j.jacc.2005.01.066
(Published online 20 July 2005). © 2005 by the American College of Cardiology Foundation |
* Division of Pediatric Cardiology, New York Presbyterian Hospital, New York, New York
University of Colorado Health Sciences Center and Pediatric Heart Lung Center, Children's Hospital, Denver, Colorado
Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
Manuscript received September 9, 2004; revised manuscript received January 6, 2005, accepted January 11, 2005.
* Reprint requests and correspondence: Dr. Erika Berman Rosenzweig, Division of Pediatric Cardiology, New York Presbyterian Hospital, 3959 Broadway, BHN 2-255, New York, New York 10032 (Email: esb14{at}columbia.edu).
OBJECTIVES: This study investigated the long-term outcome of children with pulmonary arterial hypertension (PAH) treated with bosentan therapy, with or without concomitant prostanoid therapy.
BACKGROUND: Bosentan, an oral endothelin ETA/ETB receptor antagonist, improves hemodynamics and exercise capacity in adults with PAH; however, limited data are available on its long-term effects in children.
METHODS: In this retrospective study, 86 children with PAH (idiopathic, associated with congenital heart or connective tissue disease) started bosentan with or without concomitant intravenous epoprostenol or subcutaneous treprostinil therapy. Hemodynamics, World Health Organization (WHO) functional class, and safety data were collected.
RESULTS: At the cutoff date, 68 patients (79%) were still treated with bosentan, 13 (15%) were discontinued, and 5 (6%) had died. Median exposure to bosentan was 14 months. In 90% of the patients (n = 78), WHO functional class improved (46%) or was unchanged (44%) with bosentan treatment. Mean pulmonary artery pressure and pulmonary vascular resistance decreased (64 ± 3 mm Hg to 57 ± 3 mm Hg, p = 0.005 and 20 ± 2 U·m2 to 15 ± 2 U·m2, p = 0.01, respectively; n = 49). Kaplan-Meier survival estimates at one and two years were 98% and 91%, respectively. The risk for worsening PAH was lower in patients in WHO functional class I/II at bosentan initiation than in patients in WHO class III/IV at bosentan initiation.
CONCLUSIONS: These data suggest that bosentan, an oral endothelin ETA/ETB receptor antagonist, with or without concomitant prostanoid therapy, is safe and efficacious for the treatment of PAH in children.
| |||||||||||
This article has been cited by other articles:
|
|
 |
|
  R. L. Benza, B. K. Rayburn, J. A. Tallaj, S. V. Pamboukian, and R. C. Bourge Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension: Long-term Efficacy and Combination With Bosentan Chest, July 1, 2008; 134(1): 139 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Ivy, A. K. Doran, K. J. Smith, G. B. Mallory Jr, M. Beghetti, R. J. Barst, D. Brady, Y. Law, D. Parker, L. Claussen, et al. Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., January 15, 2008; 51(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Mache, A Gamillscheg, H H Popper, and S G Haworth Early-life pulmonary arterial hypertension with subsequent development of diffuse pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia type 1 Thorax, January 1, 2008; 63(1): 85 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines Chest, June 1, 2007; 131(6): 1917 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M D'Alto, C D Vizza, E Romeo, R Badagliacca, G Santoro, R Poscia, B Sarubbi, M Mancone, P Argiento, F Ferrante, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart, May 1, 2007; 93(5): 621 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart, March 1, 2007; 93(3): 350 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug. Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Rosenzweig, D. D. Ivy, A. Widlitz, A. Doran, L. R. Claussen, D. Yung, S. H. Abman, and R. J. Barst Reply J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1915 - 1915. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Standing Long-Term Bosentan Treatment in Children With Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1914 - 1915. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bush Update in pediatrics 2005. Am. J. Respir. Crit. Care Med., March 15, 2006; 173(6): 585 - 592. [Full Text] [PDF]
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas Highlights of the Year in JACC 2005 J. Am. Coll. Cardiol., January 3, 2006; 47(1): 184 - 202. [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
